Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Lovell

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
British Journal of Cancer|November 14, 2014
A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177E X Chen, S Hotte, H Hirte, et al.
Journal of the American Chemical Society|July 18, 2001
C--N bond formation on addition of aryl carbanions to the electrophilic nitrido ligand in TpOs(N)Cl(2)T J Crevier, B K Bennett, J D Soper, et al.
ACS Chemical Biology|July 29, 2022
Serum-Stable and Selective Backbone-N-Methylated Cyclic Peptides That Inhibit Prokaryotic Glycolytic MutasesR H P van Neer, P K Dranchak, L Liu, et al.
JAMA Network Open|August 16, 2020
Association of Pregnancy and Insurance Status With Treatment Access for Opioid Use DisorderStephen W Patrick, Michael R Richards, William D Dupont, et al.
Biomaterials|July 27, 2010
Liquid-crystalline aromatic-aliphatic copolyester bioresorbable polymersHoracio Montes de Oca, Joanne E Wilson, Andrew Penrose, et al.
The New England Journal of Medicine|April 15, 2014
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosisFred Poordad, Christophe Hezode, Roger Trinh, et al.
Hepatology (Baltimore, Md.)|January 28, 2017
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatmentFred Poordad, Franco Felizarta, Armen Asatryan, et al.
Hepatology (Baltimore, Md.)|September 20, 2017
Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trialDavid Wyles, Fred Poordad, Stanley Wang, et al.
The American Journal of Gastroenterology|September 1, 2021
High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal AdherencePhilippe J Zamor, Ashley Brown, Douglas E Dylla, et al.
Neurosurgical Focus|December 16, 2006
Phase II study of carboplatin (CBDCA) in progressive low-grade gliomasA Moghrabi, H S Friedman, D M Ashley, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
British Journal of Cancer|November 14, 2014
A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177E X Chen, S Hotte, H Hirte, et al.
Journal of the American Chemical Society|July 18, 2001
C--N bond formation on addition of aryl carbanions to the electrophilic nitrido ligand in TpOs(N)Cl(2)T J Crevier, B K Bennett, J D Soper, et al.
ACS Chemical Biology|July 29, 2022
Serum-Stable and Selective Backbone-N-Methylated Cyclic Peptides That Inhibit Prokaryotic Glycolytic MutasesR H P van Neer, P K Dranchak, L Liu, et al.
JAMA Network Open|August 16, 2020
Association of Pregnancy and Insurance Status With Treatment Access for Opioid Use DisorderStephen W Patrick, Michael R Richards, William D Dupont, et al.
Biomaterials|July 27, 2010
Liquid-crystalline aromatic-aliphatic copolyester bioresorbable polymersHoracio Montes de Oca, Joanne E Wilson, Andrew Penrose, et al.
The New England Journal of Medicine|April 15, 2014
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosisFred Poordad, Christophe Hezode, Roger Trinh, et al.
Hepatology (Baltimore, Md.)|January 28, 2017
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatmentFred Poordad, Franco Felizarta, Armen Asatryan, et al.
Hepatology (Baltimore, Md.)|September 20, 2017
Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trialDavid Wyles, Fred Poordad, Stanley Wang, et al.
The American Journal of Gastroenterology|September 1, 2021
High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal AdherencePhilippe J Zamor, Ashley Brown, Douglas E Dylla, et al.
Neurosurgical Focus|December 16, 2006
Phase II study of carboplatin (CBDCA) in progressive low-grade gliomasA Moghrabi, H S Friedman, D M Ashley, et al.
Pageof 7